

Sylvain A Lother

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8103811/sylvain-a-lother-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

16 papers	1,439 citations	11 h-index	17 g-index
17 ext. papers	1,802 ext. citations	7.8 avg, IF	4.61 L-index

#	Paper	IF	Citations
16	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021 , 72, e835-e843	11.6	59
15	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2020 , 67, 1201-1211	3	15
14	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 517-525	59.2	803
13	Ramping Up the Delivery of Cardiac Surgery During the COVID-19 Pandemic: A Guidance Statement From the Canadian Society of Cardiac Surgeons. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 1139-1143	3.8	17
12	Adult Cardiac Surgery and the COVID-19 Pandemic: Aggressive Infection Mitigation Strategies Are Necessary in the Operating Room and Surgical Recovery. <i>Annals of Thoracic Surgery</i> , 2020 , 110, 707-711	2.7	25
11	Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 2020 ,		8
10	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa500	1	26
9	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 623-631	8	298
8	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa130	1	122
7	A case of mumps-associated myocarditis. <i>Jammi</i> , 2018 , 3, 149-154	1.4	
6	Clonal Clusters and Virulence Factors of Group C and G Streptococcus Causing Severe Infections, Manitoba, Canada, 2012-2014. <i>Emerging Infectious Diseases</i> , 2017 , 23, 1079-1088	10.2	11
5	Once-Daily Treatments for Methicillin-Susceptible Staphylococcus aureus Bacteremia: Are They Good Enough?. <i>Current Infectious Disease Reports</i> , 2017 , 19, 43	3.9	7
4	Emerging group C and group G streptococcal endocarditis: A Canadian perspective. <i>International Journal of Infectious Diseases</i> , 2017 , 65, 128-132	10.5	11
3	Tick paralysis. <i>Cmaj</i> , 2017 , 189, E1341	3.5	0
2	Antiestrogen use and survival of women with non-small cell lung cancer in Manitoba, Canada. <i>Hormones and Cancer</i> , 2013 , 4, 270-6	5	23
1	Post-exposure Prophylaxis or Preemptive Therapy for SARS-Coronavirus-2: Study Protocol for a Pragmatic Randomized Controlled Trial		1